The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (ILD), acute and/or severe (may cause ARDS)

Publications

Murakami Y, Fujita T, Wakatabe Y, Iwamura M

A Fatal Case of Life-Threatening Interstitial Pneumonitis Induced by Everolimus for Metastatic Renal Cell Carcinoma: A Comment about the Increased Risk of Interstitial Lung Disease in Japanese.

Case reports in urology 2019;2019;2703871 — 2019 — 2703871

Tejwani V, Panchabhai TS, Kotloff RM, Mehta AC

Complications of Lung Transplantation: A Roentgenographic Perspective.

Chest 2016 06;149;1535-45 — 2016 06 — 1535-45

Atkinson BJ, Cauley DH, Ng C, Millikan RE, Xiao L, Corn P, Jonasch E, Tannir NM

Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes.

BJU international 2014 Mar;113;376-82 — 2014 Mar — 376-82

Iacovelli R, Palazzo A, Mezi S, Morano F, Naso G, Cortesi E

Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials.

Acta oncologica (Stockholm, Sweden) 2012 Sep;51;873-9 — 2012 Sep — 873-9

Albiges L, Chamming's F, Duclos B, Stern M, Motzer RJ, Ravaud A, Camus P

Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology 2012 Aug;23;1943-53 — 2012 Aug — 1943-53